CSIMarket Company Name, Ticker, Industry, else..
 
Nabriva Therapeutics Plc  (NASDAQ: NBRV)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 3
 Employees 40
 Revenues (TTM) (Millions $) 30
 Net Income (TTM) (Millions $) -55
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 0

Nabriva Therapeutics Plc
Nabriva Therapeutics Plc is a biopharmaceutical company that develops and commercializes novel therapies to treat serious infections. The company is focused on the development of new antibiotics for the treatment of infections caused by drug-resistant bacteria.

Nabriva was founded in 2006 and is headquartered in Dublin, Ireland, with operations in the United States. The company is traded on the NASDAQ under the ticker symbol "NBRV."

The company's lead product is Xenleta (lefamulin), which is a first-in-class semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired pneumonia (CAP). Xenleta is approved by the FDA in both intravenous (IV) and oral formulations for the treatment of CAP in adults. It is also approved in the European Union for the treatment of community-acquired pneumonia in adults.

In addition to Xenleta, Nabriva has a pipeline of antibacterial agents, including a second-generation pleuromutilin antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI), which is currently in Phase 3 clinical development.

Nabriva also has a research and development collaboration with the Chinese pharmaceutical company, Sinovant Sciences, focused on the development of new drugs to address the growing problem of bacterial resistance in China.

Overall, Nabriva is a clinical-stage biopharmaceutical company focused on the development of innovative antibiotics to combat serious infections caused by drug-resistant bacteria. The company is committed to creating new treatment options for healthcare providers and patients, and to helping address the global public health threat of antibiotic-resistant infections.


   Company Address: 25-28 North Wall Quay Dublin 1 0
   Company Phone Number: 649 2000   Stock Exchange / Ticker: NASDAQ NBRV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BTAI        17.75% 
JAGX        79.76% 
SCYX        2.05% 
TBPH        0.53% 
• View Complete Report
   



Nabriva Therapeutics Plc

Nabriva Therapeutics Plc's Financial Performance Shows Alarming Losses in Q2 2023

Nabriva Therapeutics Plc is a pharmaceutical company that focuses on the development and commercialization of novel antibiotics to treat serious infections. However, recent financial results have indicated a significant decline in revenue and an increase in net deficit per share for the fiscal period ending June 30, 2023.
The company announced that its revenue had decreased by a staggering 75.596% to $2.24 million compared to the corresponding reporting period from the previous year. This decline is quite concerning, especially when considering that the overall Major Pharmaceutical Preparations sector experienced a 3.01% gain in revenue during the second quarter of 2023.
Nabriva Therapeutics Plc

Stormy First Quarter for Nabriva Therapeutics: Plunge of 5.362% in Revenue and Skyrocketing Shortfall per Share of $-2.72

Nabriva Therapeutics Plc, a biopharmaceutical company specializing in the development of novel antibiotics for the treatment of bacterial infections, has reported a significant increase in shortfall per share for the January to March 31, 2023 interval. The company's shortfall per share increased to $-2.72 per share, compared to $-0.20 per share in the same period a year prior, and grew from $-0.36 per share in the previous quarter.
The company's revenue also decreased by -5.362% to $7.59 million from $8.02 million in the same period a year prior, and sequentially revenue fell by -28.2% from $10.57 million. Despite this decline in revenue, Nabriva Therapeutics Plc reported a net shortfall of $-8.700 million for the January to March 31, 2023 interval, which is an improvement compared to the deficit of $-11.819 million in the same quarter a year ago.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com